Monthly Archives: January 2018

Non-adherence to medications is common in patients with inflammatory bowel disease (IBD). The aim of this study was to assess adherence to biologic medications prescribed for IBD, and to identify risk factors for biologic non-adherence. Continue reading →

Standard weight-based infliximab (IFX) dosing for inflammatory bowel disease (IBD) results in long-term clinical remission in only 40-60% of patients. Patient and disease factors account for variability in IFX exposure. Achieving optimal IFX exposure a… Continue reading →

Patients hoping to improve their understanding of treatments recommended by their providers frequently turn to the Internet as their source of information. Medical foods are emerging adjunct treatments in Inflammatory Bowel Diseases (IBD) with a growin… Continue reading →

We sought to analyze whether response to second-line biologic varies depending on reason for discontinuation of primary anti-TNF agent (primary non-response [PNR], secondary loss of response [LOR] after initial response, or intolerance), through a syst… Continue reading →

The aim of this study was to investigate the predictors of short- and long-term clinical response to the initial anti-TNFs in moderate to severe ulcerative colitis (UC) patients. Continue reading →

Inflammatory Bowel Disease is a group of chronic and relapsing diseases that can be associated with poor nutrient absorption. Despite the rise in biologics, there are patients unable to maintain remission. Hence there is a rising interest for medical f… Continue reading →

Patients with inflammatory bowel disease (IBD) without adequate access to urgent medical care for exacerbation of symptoms tend to obtain care from emergency departments (ED), which is associated with an increased use of opiates, steroids, and poor pat… Continue reading →

Anemia is a common but under-recognized complication of inflammatory bowel diseases (IBD). Anemia in IBD is associated with increased resource utilization and reduced quality of life, yet screening and management of anemia among IBD patients is poor. T… Continue reading →

Tofacitinib is an oral, small molecule Janus kinase (JAK) inhibitor that is being investigated for IBD. In a recent trial of Crohn’s disease (CD) patients (pts), small treatment effects for tofacitinib vs placebo (PBO) were noted using CD Activity In… Continue reading →

Optimal inflammatory bowel disease (IBD) therapy often requires biologic medications delivered by intravenous (IV) infusion. Until recently, infusions were generally delivered in supervised hospital or outpatient clinics. As insurance companies attempt… Continue reading →